Marion Thibaudin

7PUBLICATIONS
29CO-AUTHORS
Innate immunityMolecular targetsSolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 22, 2026
IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapy.

|Nov 06, 2025
Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T-cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite-Stable Colorectal Cancer.

Jean-David Fumet, Charlène Latour, Lisa Nuttin

|Jan 17, 2025
Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.

Marion Thibaudin, Nicolas Roussot, Chloé Burlot

|Dec 08, 2023
Targeting CTLA-4: a possible solution for microsatellite-stable colorectal cancer.

François Ghiringhelli, Marion Thibaudin

|Aug 10, 2023
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.

Marion Thibaudin, Jean-David Fumet, Benoist Chibaudel

|May 25, 2022
Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects.

Romain Mary, Fanny Chalmin, Théo Accogli

Pageof 2

Frequent Collaborators

4 joint publications

François Ghiringhelli

3 joint publications

Caroline Truntzer

2 joint publications

Mélanie Bruchard

2 joint publications

Frédérique Végran